By tracking patent expirations, patent litigation, generic and biosimilar development, you can anticipate these market-shaping forces and stay one step ahead.
DrugPatentWatch Database Preview
Details for New Drug Application (NDA): 019219
Email this page to a colleague
NDA 019219 describes BETAGAN, which is a drug marketed by Allergan and is included in two NDAs. Additional details are available on the BETAGAN profile page.
The generic ingredient in BETAGAN is levobunolol hydrochloride. There are seven drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the levobunolol hydrochloride profile page.
The generic ingredient in BETAGAN is levobunolol hydrochloride. There are seven drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the levobunolol hydrochloride profile page.
Summary for 019219
| Tradename: | BETAGAN |
| Applicant: | Allergan |
| Ingredient: | levobunolol hydrochloride |
| Patents: | 0 |
Pharmacology for NDA: 019219
| Mechanism of Action | Adrenergic beta-Antagonists |
Medical Subject Heading (MeSH) Categories for 019219
Profile for product number 002
| Active Rx/OTC/Discontinued: | RX | Dosage: | SOLUTION/DROPS;OPHTHALMIC | Strength | 0.5% | ||||
| Approval Date: | Dec 19, 1985 | TE: | AT | RLD: | Yes | ||||
Expired US Patents for NDA 019219
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Allergan | BETAGAN | levobunolol hydrochloride | SOLUTION/DROPS;OPHTHALMIC | 019219-002 | Dec 19, 1985 | Try Before You Buy | Try Before You Buy |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Complete Access Available with Subscription
